Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its proprietary PDAOAI drug discovery and development platform will be featured during the Product & Engineering keynote at Qdrant Vector Space Day 2026 in San Francisco on June 11. Company executives will join Qdrant leadership to discuss how PDAOAI, operating on Qdrant infrastructure, has helped accelerate the development of two drug candidates from concept to investigational new drug filings in less than two years, significantly reducing the time and cost traditionally associated with pharmaceutical development.
The presentation will highlight several innovations underpinning the platform, including a proprietary “manifold folding” technique designed to improve semantic retrieval accuracy and reduce large language model hallucinations, as well as the indexing of approximately 28 million PubMed biomedical abstracts on Qdrant Cloud. Oncotelic said the platform leverages advanced vector search technologies to support large-scale biomedical research and accelerate oncology drug discovery efforts.
This announcement underscores the growing importance of artificial intelligence in pharmaceutical research. By integrating vector search and large language models, Oncotelic's PDAOAI platform addresses two critical bottlenecks in drug development: the immense time required to identify viable drug candidates and the high cost of bringing a drug to market. The ability to file INDs for two candidates in under two years is a significant achievement, as traditional drug development often takes a decade or more. This efficiency could translate into faster access to novel therapies for patients with high-unmet-need cancers and rare pediatric indications.
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products. The company leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration. In addition to its directly owned pipeline, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures, including a 45% interest in GMP Bio.
The event at Qdrant Vector Space Day 2026 highlights the convergence of AI infrastructure and biotech innovation. Oncotelic's collaboration with Qdrant, a provider of vector search technology, demonstrates how specialized AI tools can be tailored for biomedical research. The company's CEO, Dr. Vuong Trieu, has filed over 500 patent applications and holds 75 issued patents, underscoring the depth of intellectual property driving the platform.
For investors and industry observers, this presentation offers a window into how AI is reshaping drug discovery. The successful use of PDAOAI to accelerate IND filings may signal broader adoption of similar technologies across the pharmaceutical sector, potentially lowering barriers to entry for smaller biotech firms and speeding the development of treatments for rare diseases.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC.
